查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1923003

放射性药物疗法市场（按治疗方法、放射性同位素、适应症、最终用户和分销管道划分）—2026-2032年全球预测

Radiopharmaceutical Therapy Market by Therapy Type, Radioisotope, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，放射性药物治疗市场规模将达到 91.8 亿美元，到 2026 年将成长至 99.7 亿美元，复合年增长率为 10.55%，到 2032 年将达到 185.2 亿美元。

关键市场统计数据
基准年 2025 91.8亿美元
预计年份：2026年 99.7亿美元
预测年份 2032 185.2亿美元
复合年增长率 (%) 10.55%

权威的放射性药物治疗指南，涵盖临床进展、营运现状以及面向整个医疗保健生态系统相关人员的策略重点。

放射性药物疗法已从一种小众临床手段转变为重塑肿瘤学和标靶疾病管理的关键治疗方法。过去十年，精准医学的进步、诊断影像技术的改进以及放射性同位素生产技术的进步，共同推动了治疗性放射性药物从实验性工具发展成为复杂适应症的临床检验治疗方案。这项发展体现在剂量测定技术的改进、伴随诊断在患者选择方面的应用，以及治疗工具库的扩展（包括α和β发射体疗法）。临床医生和医疗系统日益认识到，这些药物并非只是挽救性疗法，而是多方面治疗路径中不可或缺的一部分。

对将重塑放射性药物疗法并加速临床整合的关键科学、监管和营运转折点进行全面分析

放射性药物治疗领域正经历着由科学突破、监管发展和基础设施日益成熟的推动而发生的变革。关键的技术转折点包括α发射体疗法的成熟，例如人们对锕-225类化合物的兴趣重燃，以及镭-223的新适应症的出现。这些药物具有更高的线性能量传递速率和靶向细胞毒性，并可能克服一些β发射体疗法的抗药性。同时，碘-131、镏-177和钇-90等β发射体疗法也持续受益于标靶化配体的改进和剂量管理的优化，从而实现了更安全的门诊给药，并能更广泛地应用于早期治疗阶段。

评估2025年贸易政策调整对放射性药物治疗的供应安全、商业策略和取得途径的多层次影响

2025年美国关税政策对整个放射性药物治疗价值链产生了复杂而多方面的影响，远非简单的成本调整所能涵盖。在营运层面，对专用设备、前驱化学品以及放射性药物生产中某些组件的进口关税上调，推高了成品治疗药物和关键原材料的到岸成本。此举对缺乏采购规模以消化额外关税的中小型製造商和学术创业公司影响尤为显着，可能导致早期临床项目延期，并减少进入后期临床试验的在临床实验药物种类。同时，依赖跨境原料和生产设备运输的同位素供应商也面临利润空间压缩，并需要与国际合作伙伴重新谈判商业条款。

可操作的细分洞察表明，不同的治疗方法类型、同位素、临床适应症、终端使用者能力和分销模式会产生不同的策略要务。

详细的市场细分揭示了不同治疗方法类型、放射性同位素、适应症、最终用户和分销管道所带来的独特机会和营运重点。依治疗方法类型划分，市场可分为α发射体治疗及β发射体治疗。 α发射体治疗包括锕-225和镭-223，它们在治疗微转移性疾病和难治性肿瘤方面显示出良好的征兆。另一方面，β发射体治疗包括碘-131、镏-177和钇-90，它们在已确立的适应症和成熟的临床通讯协定中占据基础地位。以放射性同位素分類的市场结构包括锕-225、碘-131、镏-177、镭-223和钇-90，每种放射性同位素都有其独特的生产、处理和剂量测定要求，这些要求会影响生产投资和临床工作流程。就适应症而言，骨转移、神经内分泌肿瘤、前列腺癌和甲状腺癌是主要的临床目标，而差异化的患者路径和证据生成的需求正在影响着该疗法的推广速度。

区域策略资讯：说明美洲、欧洲、中东和非洲以及亚太地区的趋势将如何影响放射性药物疗法的采用、生产和取得。

区域趋势对全球临床应用、生产策略和监管方式具有决定性影响。在美洲，某些市场先进的报销体系、能够支持复杂剂量测定和住院服务的庞大医院网络，以及对国内同位素生产的集中投资，正在推动临床应用。这些因素共同为高度复杂治疗方法的早期商业化创造了有利环境，而支付方的审查和区域采购惯例则影响着应用顺序和定价策略。欧洲、中东和非洲地区的监管环境复杂多元，既有集中监管途径，也有国家层级的资金决策。虽然一些欧洲国家拥有强大的製造群和成熟的核医学专业知识，但预算限制和不同的卫生技术评估要求可能导致医疗服务取得不均衡。同时，中东地区正在加大对卓越医疗中心的投资，以吸引跨国患者，而非洲部分地区基础设施和人力资源的匮乏则限制了短期内的应用。

赞助商、同位素生产商、合约研发生产机构 (CDMO) 和临床创新者之间的竞争与合作策略，定义了放射性药物治疗领域的竞争优势。

产业相关人员正采取多元化的策略性倡议，以巩固其在放射性药物治疗领域的主导地位，这些倡议包括整合专有技术、投资生产能力以及建立合作网络。拥有肿瘤产品组合的製药公司正将放射性药物候选药物整合到广泛的治疗领域，利用其临床试验基础设施加速核准审批流程，并与专业生产商签订许可协议以扩大供应规模。专注于同位素生产和放射化学服务的公司则正投资于产能扩张、自动化和品质体系建设，以满足不断变化的市场需求，并为寻求可预测供应链的申办者提供承包解决方案。

为产业领导者提供切实可行的优先建议，以增强供应韧性、加快证据产生并确保放射性药物疗法的报销途径。

致力于将科学进步转化为永续的临床和商业性成功的领导者应采取一系列切实有效的行动。首先，优先考虑供应链的韧性，并考虑实现同位素来源多元化、评估区域生产伙伴关係，以及比较近岸外包与长期供应协议的经济效益。其次，将临床开发与真实世界证据的产生相结合，并设计包含标准化剂量测定、患者报告结局和卫生经济学终点的註册试验，以促进与支付方的讨论并加速技术应用。第三，透过针对核医团队的专项训练、简化门诊诊所的物流解决方案、减少医院行政管理摩擦的服务模式，加强对终端用户的支持力道。

报告的基本调查方法采用了一种透明、多方面的方法，结合了专家访谈、技术检验、情境分析和监管审查，旨在得出切实可行的结论。

本报告的研究采用了多源三角验证调查方法，旨在确保研究结果的有效性、相关性和可操作性。主要资料来源包括对医院系统临床研究人员、生产专家、监管顾问和采购人员的结构化访谈，以了解实际营运和策略意图。二级资讯来源资讯来源同行评审文献、临床试验註册信息、监管指导文件、生产白皮书和上市公司披露信息，以提供背景信息和佐证细节。技术论证则透过咨询剂量学专家和放射化学从业人员获得，以确保操作建议符合当前的最佳实践。

本文简明扼要地总结了放射性药物治疗这一不断发展的领域中，定义成功的临床预期、营运挑战和策略重点。

放射性药物疗法正处于一个转折点，科学进步、基础设施投资和政策变革相互作用，既带来了巨大的机会，也带来了巨大的风险。临床进展，特别是α发射体和精准靶向β发射体的进展，正在拓展骨转移、神经内分泌肿瘤、前列腺癌和甲状腺癌等适应症的治疗选择。然而，要充分发挥这些潜力，需要实际解决供应链复杂性、生产规模扩大和支付方接受度等挑战。预计2025年实施的关税主导环境，将透过重塑成本结构和推动生产及分销的策略调整，进一步加速这些趋势的发展。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗方法的放射性药物治疗市场

  • α粒子疗法
    • 锕-225
    • 镭-223
  • β射线疗法
    • 碘-131
    • 镏-177
    • 钇-90

9. 按放射性同位素分類的放射性药物治疗市场

  • 锕-225
  • 碘-131
  • 镏-177
  • 镭-223
  • 钇-90

第十章 依适应症分類的放射性药物治疗市场

  • 骨转移
  • 神经内分泌肿瘤
  • 摄护腺癌
  • 甲状腺癌

第十一章 依最终用户分類的放射性药物治疗市场

  • 医院
  • 研究所
  • 专科诊所

第十二章 放射性药物治疗市场（依分销管道划分）

  • 离线
  • 在线的

第十三章 放射性药物治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 放射性药物治疗市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国放射性药物治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国放射性药物治疗市场

第十七章：中国放射性药物治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • AdvanCell Isotopes Pty Ltd.
  • Aktis Oncology Inc.
  • Alpha Tau Medical Ltd.
  • Ariceum Therapeutics GmbH
  • ARTBIO Inc.
  • Bayer AG
  • Blue Earth Therapeutics Ltd.
  • BWXT Medical Ltd.
  • Cellectar Biosciences, Inc.
  • Clarity Pharmaceuticals Ltd.
  • Convergent Therapeutics, Inc.
  • Eckert & Ziegler AG
  • Eli Lilly and Company
  • Full-Life Technologies Ltd.
  • Fusion Pharmaceuticals Inc.
  • GE HealthCare Technologies Inc.
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Oncoinvent ASA
  • Perspective Therapeutics Inc.
Product Code: MRR-867BED9A9EB9

The Radiopharmaceutical Therapy Market was valued at USD 9.18 billion in 2025 and is projected to grow to USD 9.97 billion in 2026, with a CAGR of 10.55%, reaching USD 18.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.18 billion
Estimated Year [2026] USD 9.97 billion
Forecast Year [2032] USD 18.52 billion
CAGR (%) 10.55%

An authoritative orientation to radiopharmaceutical therapy that frames clinical advances, operational realities, and strategic priorities for stakeholders across the healthcare ecosystem

Radiopharmaceutical therapy has transitioned from a niche clinical approach into a pivotal modality reshaping oncology and targeted disease management. Over the past decade, the convergence of precision medicine, improved imaging modalities, and advances in radioisotope production has elevated therapeutic radiopharmaceuticals from experimental tools into clinically validated options for complex indications. This evolution reflects improvements in dosimetry, patient selection using companion diagnostics, and an expanding therapeutic toolkit that includes both alpha and beta emitter therapies. Clinicians and health systems are increasingly viewing these agents not only as salvage therapies but as integral components of multimodal care pathways.

The clinical promise is matched by a material transformation across the ecosystem that includes manufacturers, contract development and manufacturing organizations, isotope suppliers, regulatory bodies, and payers. Innovations in generator technologies and centralized production have addressed some historical bottlenecks, while increased commercial interest has driven investment into new isotopes and delivery systems. At the same time, constraints remain: complex logistics, stringent cold chain requirements, specialized workforce needs, and evolving reimbursement frameworks all affect uptake. Stakeholders who understand these operational dynamics and the interplay between clinical evidence generation and commercialization will be best positioned to translate scientific progress into accessible therapies for patients. As a result, decision-makers must align clinical development with pragmatic manufacturing and distribution strategies to realize the full potential of radiopharmaceutical therapy.

Comprehensive analysis of the major scientific, regulatory, and operational inflection points reshaping radiopharmaceutical therapy and accelerating clinical integration

The landscape of radiopharmaceutical therapy is undergoing transformative shifts driven by scientific breakthroughs, regulatory momentum, and infrastructural maturation. A major technical shift is the maturation of alpha emitter therapies, exemplified by renewed interest in actinium-225-based compounds and renewed applications for radium-223, which offer higher linear energy transfer and targeted cytotoxicity that can overcome some forms of resistance to beta emitters. Concurrently, beta emitter therapies such as iodine-131, lutetium-177, and yttrium-90 continue to benefit from improved targeting ligands and better dosimetric control, enabling safer outpatient administration and broader integration into earlier lines of therapy.

Parallel to therapeutic innovations are changes in how therapies are developed and delivered. Theranostic paradigms that pair diagnostic imaging with therapeutic agents are accelerating patient selection and adaptive dosing strategies, while standardized dosimetry is gaining traction as a tool to individualize treatment and enhance safety. On the manufacturing front, investments in domestic isotope production capacity, cold-chain logistics, and automated radiochemistry platforms are reshaping supply assurance and reducing cycle times. Regulatory agencies in multiple jurisdictions are also adapting, with clearer pathways for accelerated approvals and conditional access where unmet need and robust biomarker-driven evidence exist. Finally, collaborative models between industry, academic centers, and specialized clinics are broadening clinical trial access and enabling pragmatic data collection. Taken together, these shifts point toward a future where radiopharmaceutical therapy is more precise, more accessible, and embedded within personalized oncology strategies.

Assessment of the multi-layered consequences of 2025 trade policy adjustments on supply stability, commercial strategies, and access pathways for radiopharmaceutical therapies

The introduction of United States tariffs in 2025 has created a complex, multi-dimensional impact across the radiopharmaceutical therapy value chain that extends beyond simple cost adjustments. At the operational level, higher import duties on specialized equipment, precursor chemicals, and certain components of radiopharmaceutical production elevate the landed cost of both finished therapies and critical inputs. This dynamic disproportionately affects smaller manufacturers and academic spinouts that lack the purchasing scale to absorb incremental tariffs, potentially slowing early-stage clinical programs and reducing the diversity of investigational products entering late-stage trials. In parallel, isotope suppliers reliant on cross-border shipments for feedstock or production apparatus face tighter margins and the need to renegotiate commercial terms with international partners.

Strategically, the tariffs have accelerated discussions about nearshoring and vertical integration among firms that view supply stability as mission critical. Companies are evaluating whether to invest in domestic cyclotron and generator capacity, localized radiochemistry facilities, and redundant supply routes to mitigate trade exposure. While capital-intensive, such investments can improve control over schedules and quality assurance. However, these shifts also create barriers to entry for new innovators, concentrate production in larger vertically integrated players, and risk reducing competitive pricing pressure over time. Clinically, the effects may be felt in procurement cycles at hospitals and specialty clinics, where tighter budgets prompt prioritization of therapies with clearer cost-effectiveness profiles. Payers and health systems are responding by tightening formulary pathways, demanding stronger real-world evidence for value, and seeking outcome-based contracting models. Ultimately, the 2025 tariff environment underscores the need for adaptive commercial models, diversified sourcing strategies, and collaborative public-private solutions to sustain the momentum of therapeutic innovation while protecting patient access.

Actionable segmentation insights revealing how therapy types, isotopes, clinical indications, end-user capabilities, and distribution models create distinct strategic imperatives

Granular segmentation reveals differentiated opportunities and operational priorities across therapy types, radioisotopes, indications, end users, and distribution channels. Based on therapy type, the market divides into alpha emitter therapy and beta emitter therapy, where alpha emitter therapy includes actinium-225 and radium-223 and offers compelling efficacy signals for micrometastatic disease and refractory tumors, while beta emitter therapy includes iodine-131, lutetium-177, and yttrium-90 and remains foundational for established indications with mature clinical protocols. Based on radioisotope, the landscape comprises actinium-225, iodine-131, lutetium-177, radium-223, and yttrium-90, each with unique production, handling, and dosimetric requirements that influence manufacturing investments and clinical workflows. For indications, the principal clinical targets are bone metastases, neuroendocrine tumors, prostate cancer, and thyroid cancer, with differentiated patient pathways and evidence-generation needs shaping adoption velocity.

End users span hospitals, research institutes, and specialty clinics, and each setting has distinct operational capabilities: hospitals often provide integrated oncology and nuclear medicine services with complex inpatient support; research institutes drive early-phase trials and translational science; and specialty clinics focus on streamlined outpatient delivery models that require optimized logistics and reimbursement navigation. Distribution channels include direct sales, distributors, and online pharmacies, and channel strategy affects lead times, cold-chain integrity, and margin structures. Taken together, these segmentations imply that successful commercial approaches will be those that align isotope selection with indication-specific clinical evidence, match manufacturing and distribution models to end-user capabilities, and tailor commercial outreach to the procurement preferences of hospitals versus specialty clinics. Pragmatic segmentation-driven portfolio planning and targeted investments in clinician education and logistics will therefore determine which programs scale most rapidly.

Regional strategic intelligence that explains how Americas, Europe, Middle East & Africa, and Asia-Pacific dynamics shape adoption, manufacturing, and access for radiopharmaceutical therapies

Regional dynamics exert a decisive influence on clinical adoption, manufacturing strategy, and regulatory approaches across the globe. In the Americas, clinical uptake is driven by advanced reimbursement frameworks in select markets, an extensive hospital network capable of supporting complex dosimetry and inpatient services, and concentrated investment in domestic isotope production. These factors combine to create an environment favorable to early commercialization of high-complexity therapies, though payer scrutiny and regional procurement practices shape launch sequencing and pricing strategies. Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where centralized regulatory pathways coexist with country-level funding decisions; several European nations have strong manufacturing clusters and established nuclear medicine expertise, yet access can be uneven due to budgetary constraints and divergent health-technology assessment requirements. In contrast, the Middle East shows growing investment in centers of excellence that aim to attract cross-border patients, while parts of Africa face infrastructure and workforce gaps that limit near-term adoption.

Asia-Pacific is characterized by rapid clinical expansion in selected markets, growing investment in cyclotron and isotope production capacity, and regulatory systems that are progressively clarifying pathways for theranostic agents. However, differences in healthcare financing, distribution infrastructure, and local manufacturing capabilities mean that strategies successful in one APAC market may not translate directly to others. Across all regions, barriers such as cold-chain logistics, workforce specialization, and local regulatory harmonization remain common constraints, while regional strengths in clinical expertise, patient volumes, or manufacturing capacity create differentiated opportunities for targeted investment and partnership models.

Competitive and collaborative strategies across sponsors, isotope producers, CDMOs, and clinical innovators that define competitive advantage in radiopharmaceutical therapy

Industry players are pursuing diverse strategic pathways to secure leadership positions in radiopharmaceutical therapy, blending proprietary science with capacity investments and collaborative networks. Pharmaceutical sponsors with oncology portfolios are integrating radiopharmaceutical candidates into broader therapeutic franchises, leveraging clinical trial infrastructures to accelerate registrational programs and forging licensing agreements with specialized manufacturers to scale supply. Companies focused on isotope production and radiochemistry services are investing in capacity expansion, automation, and quality systems to meet evolving demand and to provide turnkey solutions for sponsors seeking predictable supply chains.

At the same time, a range of smaller biotech firms and academic spinouts are differentiating through novel targeting ligands, enhanced chelation chemistry, and improved dosimetry approaches; these entities often rely on strategic partnerships with larger firms for late-stage development and commercialization. Contract manufacturers and logistics specialists are sharpening their value propositions by certifying regulatory compliance, optimizing cold-chain protocols, and developing satellite production models that shorten lead times. Across the ecosystem, competitive advantage increasingly hinges on the ability to demonstrate integrated capabilities: reliable isotope sourcing, repeatable manufacturing workflows, and robust clinical data generation that supports payer conversations. Strategic M&A, capacity-sharing consortia, and public-private partnerships are likely to continue shaping the competitive landscape as firms seek to secure both supply resilience and clinical leadership.

Practical and prioritized recommendations for industry leaders to build supply resilience, accelerate evidence generation, and secure reimbursement pathways for radiopharmaceutical therapies

Leaders seeking to translate scientific progress into sustainable clinical and commercial success should pursue a set of pragmatic, high-impact actions. First, prioritize supply resilience by diversifying isotope sourcing, evaluating regional production partnerships, and assessing the economics of nearshoring versus long-term supplier agreements. Second, align clinical development with real-world evidence generation by designing registrational trials that incorporate standardized dosimetry, patient-reported outcomes, and health-economic endpoints to ease payer discussions and accelerate adoption. Third, invest in end-user enablement through targeted education for nuclear medicine teams, streamlined logistics solutions for outpatient clinics, and service models that reduce administrative friction for hospitals.

Fourth, engage proactively with regulators and health-technology assessment bodies to define acceptable evidence packages and to explore conditional-access pathways where unmet need is high. Fifth, adopt flexible commercial models that include value-based contracting or outcomes-linked agreements to mitigate reimbursement risk and demonstrate long-term value. Sixth, expand internal capabilities in radiochemistry automation, quality systems, and digital tracking to reduce cycle times and ensure compliance across jurisdictions. Finally, cultivate strategic alliances with academic centers and specialized clinics to accelerate clinical validation, broaden trial access, and build the real-world datasets necessary for payer acceptance. Executed cohesively, these measures will enable organizations to capture clinical upside while managing operational and commercial risk in an evolving policy and supply environment.

Transparent, multi-source research methodology combining expert interviews, technical validation, scenario analysis, and regulatory review to support actionable conclusions

The research underpinning this report synthesizes a multi-source, triangulated methodology designed to ensure validity, relevance, and actionable insight. Primary inputs included structured interviews with clinical investigators, manufacturing experts, regulatory advisers, and procurement leads at hospital systems to capture operational realities and strategic intent. Secondary sources comprised peer-reviewed literature, clinical trial registries, regulatory guidance documents, manufacturing white papers, and open-source company disclosures to provide context and corroborative detail. Technical validation was achieved through consultation with dosimetry specialists and radiochemistry practitioners to ensure that operational recommendations reflect current best practices.

Analytical methods combined qualitative thematic analysis with scenario-based assessments to explore how variables such as supply constraints, trade policy shifts, and reimbursement changes could influence strategic outcomes. Where appropriate, sensitivity analyses were used to stress-test assumptions related to production lead times, clinical adoption rates, and distribution complexity. The research team also conducted a review of relevant patent landscapes and collaboration networks to map capability clusters and potential partnership pathways. Limitations include variability in national regulatory implementations and the evolving nature of early clinical data for emerging alpha-emitter therapies; these uncertainties were addressed by presenting multiple scenarios and flagging areas where ongoing data collection is required. The overall approach emphasizes transparency, repeatable methods, and collaboration with domain experts to produce findings that are both credible and practicable.

Concise synthesis of clinical promise, operational challenges, and strategic priorities that define success in the evolving radiopharmaceutical therapy landscape

Radiopharmaceutical therapy stands at an inflection point where scientific momentum, infrastructural investment, and evolving policy interact to create both substantive opportunity and meaningful risk. Clinical advances-particularly in alpha emitter agents and precision-targeted beta emitters-are expanding therapeutic options for indications such as bone metastases, neuroendocrine tumors, prostate cancer, and thyroid cancer. Yet the realization of that promise depends on pragmatic solutions to supply-chain complexity, manufacturing scale-up, and payer acceptance. The tariff-driven environment introduced in 2025 amplifies these dynamics by reshaping cost structures and incentivizing strategic reconfiguration of production and distribution.

For stakeholders, the imperative is clear: align clinical development with durable operational models, invest in supply resilience, and produce the real-world evidence necessary to secure reimbursement and sustained patient access. Organizations that proactively address workforce development, regulatory engagement, and manufacturing agility will not only navigate near-term headwinds but will also establish durable competitive advantages. In sum, radiopharmaceutical therapy is poised to become an increasingly mainstream element of precision oncology, but success will require integrated strategies that bridge science, supply, and commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiopharmaceutical Therapy Market, by Therapy Type

  • 8.1. Alpha Emitter Therapy
    • 8.1.1. Actinium-225
    • 8.1.2. Radium-223
  • 8.2. Beta Emitter Therapy
    • 8.2.1. Iodine-131
    • 8.2.2. Lutetium-177
    • 8.2.3. Yttrium-90

9. Radiopharmaceutical Therapy Market, by Radioisotope

  • 9.1. Actinium-225
  • 9.2. Iodine-131
  • 9.3. Lutetium-177
  • 9.4. Radium-223
  • 9.5. Yttrium-90

10. Radiopharmaceutical Therapy Market, by Indication

  • 10.1. Bone Metastases
  • 10.2. Neuroendocrine Tumors
  • 10.3. Prostate Cancer
  • 10.4. Thyroid Cancer

11. Radiopharmaceutical Therapy Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Radiopharmaceutical Therapy Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Radiopharmaceutical Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Radiopharmaceutical Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Radiopharmaceutical Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Radiopharmaceutical Therapy Market

17. China Radiopharmaceutical Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actinium Pharmaceuticals, Inc.
  • 18.6. AdvanCell Isotopes Pty Ltd.
  • 18.7. Aktis Oncology Inc.
  • 18.8. Alpha Tau Medical Ltd.
  • 18.9. Ariceum Therapeutics GmbH
  • 18.10. ARTBIO Inc.
  • 18.11. Bayer AG
  • 18.12. Blue Earth Therapeutics Ltd.
  • 18.13. BWXT Medical Ltd.
  • 18.14. Cellectar Biosciences, Inc.
  • 18.15. Clarity Pharmaceuticals Ltd.
  • 18.16. Convergent Therapeutics, Inc.
  • 18.17. Eckert & Ziegler AG
  • 18.18. Eli Lilly and Company
  • 18.19. Full-Life Technologies Ltd.
  • 18.20. Fusion Pharmaceuticals Inc.
  • 18.21. GE HealthCare Technologies Inc.
  • 18.22. Jubilant Pharmova Limited
  • 18.23. Lantheus Holdings, Inc.
  • 18.24. Novartis AG
  • 18.25. Oncoinvent ASA
  • 18.26. Perspective Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BONE METASTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BONE METASTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BONE METASTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THYROID CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THYROID CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)